Assort Health
An AI agents platform handling the entire patient journey — how a single phone call became the standard for healthcare administrative automation
Assort Health is a healthcare AI agents company co-founded in 2023 in San Francisco by Jon Wang and Jeffery Liu. The two founders, who were searching for co-founders independently while living roughly 2,500 miles apart (Liu in San Francisco, Wang in New York), were connected through a “co-founder dating” questionnaire devised by First Round Capital. The questionnaire poses governance and stress-response questions such as “Can one co-founder fire another co-founder?” — a practice that has since become embedded in Assort Health’s hiring process, with every new employee completing the same questionnaire today.
The company formally launched with a $3.5 million seed round in March 2024 from Four Acres and Tau Ventures, and began drawing significant industry attention after closing a Series A in April 2025 co-led by First Round Capital and Chemistry (a new venture fund co-founded by Kristina Shen, formerly of Andreessen Horowitz). A subsequent series of rounds — Series B in September 2025 and Series C in June 2026 — brought total capital raised to more than $222 million, a trajectory that has earned the company placement on industry lists including Forbes’ “Next Billion-Dollar Startups,” CB Insights’ “AI 100,” and the Redpoint AI64.
Trained at Stanford University and UCSF School of Medicine. Background as an applied AI researcher, with prior work on deep learning for medical imaging (reducing DVT misdiagnosis) and patient-routing algorithms. Oversees finance, operations, and sales within the company and is described as the more reserved of the two co-CEOs. Has led development of specialty-specific generative voice AI directly impacting more than 9 million patient interactions.
B.S. in Computer Science and Economics from Duke University. Previously a Senior Software Engineer at Meta (Oculus and Marketplace) and Head of Product Engineering at Athelas, with prior research experience in cybersecurity and materials science. Oversees the company’s engineering, product, and design (EPD) organization as well as customer implementation and success, and serves as the company’s primary driver of product velocity.
The two founders have clearly delineated roles — one a “careful operator,” the other a “driving product leader” — and Wang has described the partnership as the fastest-moving professional relationship of his career. From an early stage, senior executives and founders from health-tech and fintech companies including Athena Health, Astrana Health, Flatiron Health, Infinitus, Mammoth Biosciences, Mercury, PathAI, and Presto have participated as angel investors, contributing both healthcare domain expertise and startup operating know-how.
Assort Health’s business model centers on an AI agents platform that automates the entire patient journey within U.S. specialty care. What began as a single voice AI agent for scheduling specialty appointments has expanded into a comprehensive platform spanning scheduling, intake forms, referral processing, document processing, medication refills, real-time insurance eligibility verification, lab requests, and payments.
| Product Line | Functional Scope | Category | Notes |
|---|---|---|---|
| Concierge | Inbound calls, triage, lab requests, medication refills, scheduling, insurance eligibility, multilingual intake | Core Product | Original flagship product; handles the full range of inbound patient touchpoints |
| Activate | Closing referral loops, automated response to care gaps (mammograms, colonoscopies, vaccines), no-show recovery, payment resolution | Outbound | Proactive patient outreach functionality for revenue recovery |
| Orchestrate | Pre/post-visit operational work, EHR documentation, automated referrals, documents, and intake forms | Back Office | Writes pre/post-visit operational workflows directly back to the EHR |
| Empower | AI copilot for staff; real-time benchmarking data for building custom agents | New | Self-serve layer allowing provider organizations to build and deploy their own AI agents |
Synapse and Patient Journey Memory: All four products are connected through Assort’s proprietary AI model, Synapse, and a continuous per-patient record system called Patient Journey Memory. Synapse learns specialty-specific workflow patterns at each deployment and automatically generates the edge cases, tests, and simulations needed, allowing even complex, provider-specific workflows to go live with high automation rates. Patient Journey Memory preserves patient context — preferred language, prior visit history, channel preference, and more — across every touchpoint to deliver one continuous experience.
As of June 2026, a key axis of business expansion is the move from provider groups into health systems. Major regional health organizations and academic medical centers — including John Muir Health — have begun partnering with Assort, reflecting growing demand for platforms capable of handling the complexity of multi-site, multi-specialty ambulatory operations.
Assort Health raised approximately $222 million cumulatively over roughly two years and three months, from its March 2024 seed round through its June 2026 Series C. Two features stand out: Series A ($22 million, April 2025) and Series B ($76 million, September 2025) were closed just four months apart, and early investors — First Round Capital, Chemistry, and Quiet Capital — participated in every subsequent round even as the investor base expanded to include large growth funds such as Menlo Ventures and Lightspeed Venture Partners.
Seed round led by Four Acres and Tau Ventures, marking the company’s formal launch. Proceeds funded early development of a generative AI solution for healthcare call center operations.
Co-led by First Round Capital and Chemistry (co-founded by Kristina Shen, formerly of a16z). Quiet Capital participated as an existing investor. Senior executives and founders from health-tech and fintech companies — including Athena Health, Astrana Health, Flatiron Health, Infinitus, Mammoth Biosciences, Mercury, PathAI, and Presto — joined as angel investors. Brought cumulative funding to $26 million.
Led by Lightspeed Venture Partners. First Round Capital and Chemistry returned as investors, joined by new participants Felicis, A*, Liquid2 Ventures, and Quiet Capital. Lightspeed’s Galym Imanbayev joined the board, and Paul Ricci, founding CEO of Nuance, joined as a board advisor. Brought cumulative funding to $102 million. The company stated the round was raised “to scale a platform solving an important patient access problem,” not to cover burn.
Led by Menlo Ventures at a $1.2 billion valuation. Existing investors Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, and Quiet Capital all returned, joined by new individual investor Joe Montana, the Hall of Fame NFL quarterback. Menlo Ventures’ JP Sanday joined the board, while partner Matt Murphy will serve as a board observer. Brought cumulative funding to more than $222 million.
The market for automating healthcare patient touchpoints includes numerous competitors — Hyro, Syllable (ActiumHealth), Infinitus Systems, Luma Health, Notable, and Hippocratic AI among them — along with adjacent competitive pressure from general-purpose contact-center automation vendors and EHR/PMS providers such as NextGen Healthcare and AdvancedMD. Assort Health’s structural differentiation can be observed across three layers: the scale of its data asset, the degree of vertical product integration, and the depth of its specialty-specific focus.
A data asset comprising more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways gives Assort a scale advantage that appears substantial relative to competitors. As interactions accumulate, the proprietary Synapse model becomes more refined — a structure in which scale economics directly translate into product-quality economics.
While many competitors focus on a single function such as scheduling or triage, Assort Health connects Concierge (inbound), Activate (outbound), Orchestrate (operations), and Empower (copilot) through Patient Journey Memory, treating the entire patient journey as one continuous system. A customer executive (MDCS Dermatology) has characterized this as the only platform of its kind they evaluated.
The product was first validated in orthopedics, a specialty where sub-specialists’ scope of practice is extremely narrow and triage complexity is high. Credibility built in this demanding environment provides a structural advantage when expanding into relatively less complex specialties such as dermatology, ophthalmology, and OB-GYN.
Native integration with more than 80 EHR/PMS systems, including Epic and Athena, enables deployment without disrupting existing clinical workflows. Customers report concrete ROI figures, including a 5% lift in appointment volume, a 115% increase in labor capacity, and up to a 75% reduction in call abandonment.
The company has stated that revenue grew 20x over the trailing 15 months. Reaching Series C roughly 14 months after Series A is a signal that the company interprets as evidence of genuine market demand and rapid product adoption.
Beyond its established strength in multi-site provider groups and multi-specialty groups, the company is expanding into large health systems and academic medical centers, including John Muir Health. Given that U.S. healthcare administrative spending totals roughly $1.1 trillion annually, this health-system push represents a strategic inflection point that meaningfully expands the addressable market.
What Anthropic-Affiliated Investor Participation Suggests: Matt Murphy, the Menlo Ventures partner who led the Series C, stated that “after investing in Anthropic, our thesis was simple: find the best application-layer companies in every category.” This statement can be read as positioning Assort Health not merely as a health-tech startup, but as a representative example of large-language-model-based agent infrastructure being applied successfully in a real industry setting — an “application-layer winner.”
Assort Health reached a $1.2 billion valuation through four funding rounds in roughly three years since its 2023 founding — an unusually rapid trajectory even by health-tech standards. However, as of this writing, the company has not disclosed specific financial metrics such as revenue, profitability, customer count, or net retention rate. The “20x revenue growth” figure cited above is based on company statements, and the underlying absolute revenue base has not been independently verified.
- Given the still-early stage of AI agent penetration within the $1.1 trillion U.S. healthcare administrative spending market, substantial long-term growth runway likely remains
- Expansion from provider groups into health systems and academic medical centers has the potential to simultaneously raise average contract value (ACV) and total addressable market
- Network effects from the data accumulated through Patient Journey Memory — where the product improves as interactions grow — may make it structurally difficult for later entrants to catch up
- Menlo Ventures’ explicit framing of Assort as an “application-layer category leader,” drawing on its Anthropic investment thesis, may support a favorable narrative for future growth-stage or IPO fundraising
- Later-stage competitors — Hyro, Syllable, Infinitus, Luma Health, Notable, Hippocratic AI, and others — are simultaneously raising large rounds, intensifying market congestion
- Limited pricing transparency and a relatively high price point (reportedly $1,500 to over $10,000 per month) have drawn some market criticism, leaving room for lower-cost alternatives to erode share
- An implementation timeline of four to eight weeks may pose an adoption barrier for smaller provider groups seeking faster ROI
- As a private company with no independent financial disclosure, investors have limited ability to directly verify core financial health indicators such as revenue, profitability, and cash burn rate
- Healthcare administrative automation is closely tied to patient safety and HIPAA compliance; any malfunction or data breach could simultaneously trigger regulatory risk and damage customer trust